Cargando…

Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults

BACKGROUND: Human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) cause respiratory tract illness in children and the elderly. No licensed vaccines are available. METHODS: In this phase 1, randomized, dose-ranging, first-in-human study, the safety, reactogenicity, and humoral immunogeni...

Descripción completa

Detalles Bibliográficos
Autores principales:	August, Allison, Shaw, Christine A, Lee, Heather, Knightly, Conor, Kalidindia, Shiva, Chu, Laurence, Essink, Brandon J, Seger, William, Zaks, Tal, Smolenov, Igor, Panther, Lori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251669/ https://www.ncbi.nlm.nih.gov/pubmed/35794943 http://dx.doi.org/10.1093/ofid/ofac206

Ejemplares similares

2754. Phase 1 Trial of an mRNA-Based Combination Vaccine Against hMPV and PIV3
por: Shaw, Christine, et al.
Publicado: (2019)

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
por: El Sahly, Hana M, et al.
Publicado: (2022)

Elimination of Aerosol Ribavirin Use in Immunocompromised Patients with Metapneumovirus and Parainfluenza Virus Infections
por: Mui, Emily, et al.
Publicado: (2017)

2655. Phase 1 Safety and Immunogenicity Results of Two Investigational mRNA Vaccines, mRNA-1345, a Respiratory Syncytial Virus Vaccine, and mRNA-1653, a Human Metapneumovirus and Parainfluenza Virus Type 3 Combination Vaccine in Seropositive Young Children
por: Snape, Matthew D, et al.
Publicado: (2023)

Virus respiratorio sincitial, metapneumovirus y virus parainfluenza humanos: cuadro clínico y fisiopatología
por: Freymuth, F.
Publicado: (2007)

Epidemiology and Clinical Presentation of Parainfluenza Type 4 in Children: A 3-Year Comparative Study to Parainfluenza Types 1–3
por: Frost, Holly M., et al.
Publicado: (2014)

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years
por: Essink, Brandon, et al.
Publicado: (2021)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy
por: Tzannou, Ifigeneia, et al.
Publicado: (2017)

Evaluation of 10 years of parainfluenza virus, human metapneumovirus, and respiratory syncytial virus infections in lung transplant recipients
por: de Zwart, Auke E. S., et al.
Publicado: (2020)

Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies
por: Sherman, Amy C, et al.
Publicado: (2022)

Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination
por: Jongkees, Marlou J, et al.
Publicado: (2022)

Population-Based Incidence of Human Metapneumovirus Infection among Hospitalized Children
por: Williams, John V., et al.
Publicado: (2010)

Role for Maternal Asthma in Severe Human Metapneumovirus Lung Disease Susceptibility in Children
por: Libster, Romina, et al.
Publicado: (2020)

Parainfluenza Virus Infection Among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Children and Adults Hospitalized for Severe Acute Respiratory Illness in South Africa, 2009–2014
por: Cohen, Adam L., et al.
Publicado: (2015)

Lipid nanoparticles for mRNA delivery
por: Hou, Xucheng, et al.
Publicado: (2021)

Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation
por: Más, Vicente, et al.
Publicado: (2016)

Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein
por: Battles, Michael B., et al.
Publicado: (2017)

Effects of Human Respiratory Syncytial Virus, Metapneumovirus, Parainfluenza Virus 3 and Influenza Virus on CD4+ T Cell Activation by Dendritic Cells
por: Le Nouën, Cyril, et al.
Publicado: (2010)

Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies
por: de Zwart, Auke, et al.
Publicado: (2021)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine
por: Peterson, James T, et al.
Publicado: (2021)

A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus
por: August, Allison, et al.
Publicado: (2021)

Author Correction: A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus
por: August, Allison, et al.
Publicado: (2022)

Effects of Prior Influenza Exposure on Immunogenicity of Influenza Vaccine
por: Cao, Jia-Qian, et al.
Publicado: (2020)

Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and Coronavirus
por: Hirsch, Hans H., et al.
Publicado: (2013)

Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study
por: Costa Clemens, Sue Ann, et al.
Publicado: (2022)

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
por: Roa, Camilo C, et al.
Publicado: (2023)

Human Metapneumovirus in Turkey Poults
por: Velayudhan, Binu T., et al.
Publicado: (2006)

Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus, and Influenza-Related Hospitalizations in Adults—A Global Study During the 2017–2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study)
por: Falsey, Ann R, et al.
Publicado: (2021)

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
por: Stieh, Daniel J, et al.
Publicado: (2022)

Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis
por: Vasconcelos, Zanair Soares, et al.
Publicado: (2023)

2892. Safety and Immunogenicity of mRNA-1647, an mRNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results of a Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial
por: Panther, Lori, et al.
Publicado: (2023)

Immunogenicity of Reduced-Dose Monovalent Type 2 Oral Poliovirus Vaccine in Mocuba, Mozambique
por: de Deus, Nilsa, et al.
Publicado: (2020)

Human Metapneumovirus
por: Hermos, Christina R., et al.
Publicado: (2010)

Human Metapneumovirus
por: Garcia–Moliner, Maria L.
Publicado: (2013)

Métapneumovirus humain
por: Freymuth, F., et al.
Publicado: (2009)

Wastewater concentrations of human influenza, metapneumovirus, parainfluenza, respiratory syncytial virus, rhinovirus, and seasonal coronavirus nucleic-acids during the COVID-19 pandemic: a surveillance study
por: Boehm, Alexandria B, et al.
Publicado: (2023)

Immunogenicity, Safety, and Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infections After Coronavirus Disease 2019 Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study
por: Kabbani, Dima, et al.
Publicado: (2023)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
por: Baden, Lindsey R., et al.
Publicado: (2020)

A systematic review of the diagnostic aspects and use of Trypanosoma rangeli as an immunogen for Trypanosoma cruzi infection
por: Bayão, Taciana de Souza, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5g1ipqp6l8gdl0i342gr8p9nd2